3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma
260
Lymphoma, Non-Hodgkin
205
Leukemia, Lymphocytic, Chronic, B-Cell
193
Lymphoma, Large B-Cell, Diffuse
187
Lymphoma, Follicular
168
Lymphoma, Mantle-Cell
134
Leukemia
81
Lymphoma, B-Cell, Marginal Zone
80
Burkitt Lymphoma
54
Waldenstrom Macroglobulinemia
52
Precursor Cell Lymphoblastic Leukemia-Lymphoma
48
Lymphoma, B-Cell
47
Lymphoma, Large-Cell, Immunoblastic
42
Hodgkin Disease
39
Recurrence
35
Lymphoma, Large-Cell, Anaplastic
18
Multiple Myeloma
16
Neoplasms
13
Myelodysplastic Syndromes
12
Hematologic Neoplasms
12
Leukemia, Myeloid, Acute
11
Lymphoma, T-Cell
9
Intraocular Lymphoma
9
Dendritic Cell Sarcoma, Interdigitating
9
Leukemia, Prolymphocytic
7
Neoplasms, Plasma Cell
6
Leukemia, Hairy Cell
6
Leukemia, B-Cell
6
Graft vs Host Disease
6
Arthritis, Rheumatoid
6
Interventions
Rituximab
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Myositis
×
Rituximab
×
Clear all
NCT00774462
2012-12-11
FORCE
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
30 enrolled